Lovastatin Enhances Chemosensitivity of Paclitaxel-Resistant Prostate Cancer Cells through Inhibition of CYP2C8

Investigators used prostate cancer cell line PC3 and its paclitaxel-resistant counterpart PC3-TxR as the cell model and suggested that lovastatin (LV) might increase the sensitivity of resistant prostate cancer cells to paclitaxel through inhibition of CYP2C8.